© 2024 Corcept Therapeutics, Incorporated
Featured
Stories
All Stories
HONORING DR. MIN CHIU LI
Article:
Corcept to Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ASCO 2025
Press Release: April 23, 2025
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes
Press Release: April 21, 2025
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Press Release: Mar 31, 2025
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
Press Release: Mar 3, 2025
A Simple Test, A Life-Changing Diagnosis: The Cortisol Connection
Article:
Honoring Rosalyn Yalow, Ph.D.
Article:
Honoring Dr. LaSalle D. Leffall Jr.
Article:
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
Press Release: Dec 30, 2024